COVID-19患者停用与继续使用肾素-血管紧张素系统抑制剂的随机对照试验
ACEI-COVID是一项在奥地利和德国35个中心进行的前瞻性、平行组、随机、对照、开放标签试验,纳入204例近期有症状的SARS-CoV-2感染且长期接受ACEI或ARB治疗的患者,随机分为停用组(n=104)和继续组(n=100)30天。主要终点30天内最大SOFA评分无显著差异,但停用组AUCSOFA、平均SOFA评分和30天SOFA评分显著更低,器官功能障碍或死亡比例显著更低。结论认为停用RAS抑制剂对最大严重程度无显著影响,但可能促进更快更好的恢复。
要点
- 停用RAS抑制剂未显著降低30天内最大SOFA评分。
- 停用组AUCSOFA、平均SOFA评分和30天SOFA评分显著更低。
- 是否停用应个体化,考虑风险、适应证及替代治疗和门诊监测条件。
核心结论
- 停用RAS抑制剂对COVID-19最大严重程度无显著影响,但可能促进更快更好的恢复。
- 是否继续或停用应个体化,考虑风险特征、RAS抑制适应证以及替代疗法和门诊监测的可及性。
研究设计与样本
- ACEI-COVID为平行组、随机、对照、开放标签试验,在奥地利和德国35个中心进行。
- 纳入204例18岁及以上、近期有症状的SARS-CoV-2感染且长期接受ACEI或ARB治疗的患者,1:1随机分为停用组(n=104)和继续组(n=100),干预30天。
- 主要终点为30天内最大SOFA评分,死亡计为最大可达SOFA评分;分析基于改良意向性治疗。
临床怎么用
- 对于长期接受ACEI或ARB治疗的COVID-19患者,停用RAS抑制剂未显著改善最大SOFA评分,但可能促进更快恢复。
- 临床决策应个体化,综合考虑患者风险特征、RAS抑制的适应证以及替代疗法和门诊监测的可及性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: SARS-CoV-2 entry in human cells depends on angiotensin-converting enzyme 2, which can be upregulated by inhibitors of the renin-angiotensin system (RAS). We aimed to test our hypothesis that discontinuation of chronic treatment with ACE-inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) mitigates the course o\f recent-onset COVID-19. METHODS: ACEI-COVID was a parallel group, randomised, controlled, open-label trial done at 35 centres in Austria and Germany. Patients aged 18 years and older were enrolled if they presented with recent symptomatic SARS-CoV-2 infection and were chronically treated with ACEIs or ARBs. Patients were randomly assigned 1:1 to discontinuation or continuation of RAS inhibition for 30 days. Primary outcome was the maximum sequential organ failure assessment (SOFA) score within 30 days, where death was scored with the maximum achievable SOFA score. Secondary endpoints were area under the death-adjusted SOFA score (AUCSOFA), mean SOFA score, admission to the intensive care unit, mechanical ventilation, and death. Analyses were done on a modified intention-to-treat basis. This trial is registered with ClinicalTrials.gov, NCT04353596. FINDINGS: Between April 20, 2020, and Jan 20, 2021, 204 patients (median age 75 years [IQR 66-80], 37% females) were randomly assigned to discontinue (n=104) or continue (n=100) RAS inhibition. Within 30 days, eight (8%) of 104 died in the discontinuation group and 12 (12%) of 100 patients died in the continuation group (p=0·42). There was no significant difference in the primary endpoint between the discontinuation and continuation group (median [IQR] maximum SOFA score 0·00 (0·00-2·00) vs 1·00 (0·00-3·00); p=0·12). Discontinuation was associated with a significantly lower AUCSOFA (0·00 [0·00-9·25] vs 3·50 [0·00-23·50]; p=0·040), mean SOFA score (0·00 [0·00-0·31] vs 0·12 [0·00-0·78]; p=0·040), and 30-day SOFA score (0·00 [10-90th percentile, 0·00-1·20] vs 0·00 [0·00-24·00]; p=0·023). At 30 days, 11 (11%) in the discontinuation group and 23 (23%) in the continuation group had signs of organ dysfunction (SOFA score ≥1) or were dead (p=0·017). There were no significant differences for mechanical ventilation (10 (10%) vs 8 (8%), p=0·87) and admission to intensive care unit (20 [19%] vs 18 [18%], p=0·96) between the discontinuation and continuation group. INTERPRETATION: Discontinuation of RAS-inhibition in COVID-19 had no significant effect on the maximum severity of COVID-19 but may lead to a faster and better recovery. The decision to continue or discontinue should be made on an individual basis, considering the risk profile, the indication for RAS inhibition, and the availability of alternative therapies and outpatient monitoring options. FUNDING: Austrian Science Fund and German Center for Cardiovascular Research.
引用
- Bauer A, Schreinlechner M, Sappler N, et al. Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. Lancet Respir Med. 2021. PMID: 34126053. doi:10.1016/S2213-2600(21)00214-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。